| Name | Danofloxacin mesylate |
| Description | Danofloxacin mesylate (CP 76136-27) is a synthetic antibacterial agent of the fluoroquinolone class that primarily inhibits bacterial DNA-gyrase. |
| In vitro | In vivo, Danofloxacin demonstrates a protective effect against Pasteurella multocida (PD50=0.38 mg/kg), Escherichia coli (PD50=0.8 mg/kg), and Salmonella Choleraesuis (PD50=2.42 mg/kg) in mice. |
| In vivo | Danofloxacin exhibits a minimum inhibitory concentration (MIC90) of 0.125μg/ml against isolates of Pasteurella haemolytica, Pasteurella multocida, and Haemophilus somnus from both Europe and North America. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.21 mM), Sonication is recommended. DMSO : 4.6 mg/mL (10.14 mM), Sonication and heating are recommended.
|
| Keywords | RNASynthesis | RNA Synthesis | Inhibitor | inhibit | DNASynthesis | DNA-gyrase | DNA Synthesis | Danofloxacin mesylate | Danofloxacin | Bacterial | Antibiotic |
| Inhibitors Related | Neomycin sulfate | Levulinic acid | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Thymidine | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Approved Drug Library | ReFRAME Related Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Drug Library |